John Hancock Multifactor Health Care ETF (JHMH) Stock Analysis
DELISTED 2022
What happened to John Hancock Multifactor Health Care ETF (JHMH) stock?
John Hancock Multifactor Health Care ETF (JHMH) no longer trades on public markets. It was delisted in October 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
John Hancock Multifactor Health Care ETF (JHMH) trades at $45.42. John Hancock Multifactor Health Care ETF (JHMH) aims to track the performance of the healthcare sector in the U. S. Market cap: $20.4M, Sector: Financial services.
Last analyzed: Mar 18, 2026Analyst Coverage for JHMH: JHMH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates JHMH against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
JHMH: the 2 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →John Hancock Multifactor Health Care ETF (JHMH) Financial Services Profile
John Hancock Multifactor Health Care ETF (JHMH) provides investors targeted exposure to the U.S. healthcare sector through a multifactor investment strategy. The fund focuses on companies with significant market capitalization, offering a non-diversified approach within the asset management landscape, appealing to investors seeking specific sector exposure.
What Is the Investment Thesis for JHMH?
JHMH presents a targeted investment vehicle for those bullish on the healthcare sector. With a beta of 0.73, the fund demonstrates lower volatility compared to the broader market, potentially offering a more stable investment within the often-turbulent healthcare industry. The fund's multifactor approach aims to enhance returns by strategically selecting securities based on value, momentum, and quality factors. Upcoming catalysts include potential advancements in healthcare technology and favorable regulatory changes that could boost the performance of healthcare companies within the fund's portfolio. However, investors should be aware of potential risks such as adverse regulatory actions, increased competition, and economic downturns that could negatively impact the healthcare sector. The fund's non-diversified nature concentrates risk, making it crucial to carefully consider the overall market conditions and healthcare industry outlook.
Based on FMP financials and quantitative analysis
JHMH Key Highlights
Market Cap of $20.4M indicates a relatively small fund size, which may lead to higher volatility and lower liquidity compared to larger ETFs.
- Beta of 0.73 suggests lower volatility compared to the overall market, potentially making it a more stable investment during market downturns.
- The fund is non-diversified, concentrating investments in a smaller number of healthcare companies, which can lead to higher potential returns but also increased risk.
- JHMH's investment strategy employs a multifactor model, considering value, momentum, and quality to select securities within the healthcare sector, aiming to enhance returns.
- The fund provides targeted exposure to the U.S. healthcare sector, allowing investors to capitalize on the growth potential of pharmaceuticals, biotechnology, healthcare equipment, and healthcare services.
Who Are JHMH's Competitors?
JHMH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLLD JPMorgan Sustainable Infrastructure ETF | $48.77 | +0.02% | $20.4M | 44 |
| DIVI Franklin International Core Dividend Tilt Index ETF | $44.28 | -0.36% | $2.59B | 48 |
| DVP Roundhill Acquirers Deep Value ETF | $21.86 | -0.62% | $20.2M | — |
| FEVR Inspire Faithward Large Cap Momentum ESG ETF | $22.41 | +0.16% | $21.6M | — |
| JHMA John Hancock Multifactor Materials ETF | $40.71 | -0.36% | $13.8M | 44 |
| BCG Binah Capital Group, Inc. | $1.40 | +0.72% | $23.5M | 78 |
| ALTEX Firsthand Alternative Energy Fund | $12.93 | -1.90% | $8.98M | 82 |
| IDKFF ThreeD Capital Inc. | $0.07 | +13.85% | $6.98M | 70 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JHMH's Key Strengths?
Targeted exposure to the U.S. healthcare sector.
- Multifactor investment approach aiming to enhance returns.
- Established brand name of John Hancock Investment Management.
- Relatively low beta of 0.73, indicating lower volatility compared to the broader market.
What Are JHMH's Weaknesses?
Non-diversified nature concentrates risk.
- Small market cap of $20.4M may lead to higher volatility and lower liquidity.
- Performance highly dependent on the healthcare sector's overall health and growth.
- No dividend yield, which may be less attractive to income-seeking investors.
What Could Drive JHMH Stock Higher?
JHMH catalyst: Potential advancements in healthcare technology, such as new drug approvals and medical device innovations, could boost the performance of healthcare companies within the fund's portfolio.
- Aging population driving increased demand for healthcare services and products, creating a long-term growth driver for the healthcare sector and the fund.
- Government initiatives and policies aimed at improving healthcare access and affordability could positively impact the healthcare industry and the fund's investments.
What Are the Key Risks for JHMH?
Adverse regulatory actions, such as drug pricing controls and changes to healthcare reimbursement policies, could negatively impact the profitability of healthcare companies.
- Increased competition among healthcare companies could lead to pricing pressures and reduced market share.
- Economic downturns could negatively impact healthcare spending, affecting the performance of healthcare companies and the fund.
- The fund's non-diversified nature concentrates risk, making it vulnerable to significant losses if a few key holdings perform poorly.
What Are the Growth Opportunities for JHMH?
- Increased Healthcare Spending: The global healthcare expenditure is projected to reach $10 trillion by 2028, driven by an aging population and rising prevalence of chronic diseases. JHMH can capitalize on this trend by investing in companies that benefit from increased healthcare spending, such as pharmaceutical companies, healthcare providers, and medical device manufacturers. This growth opportunity presents a long-term catalyst for the fund's performance.
- Technological Advancements: The healthcare industry is undergoing a technological revolution, with innovations in areas such as telemedicine, artificial intelligence, and genomics. JHMH can benefit from these advancements by investing in companies that are at the forefront of healthcare technology. The adoption of new technologies is expected to drive efficiency and improve patient outcomes, creating significant growth opportunities for the fund.
- Aging Population: The global population is aging rapidly, with the number of people aged 65 and over projected to double by 2050. This demographic shift will drive demand for healthcare services and products, creating opportunities for JHMH to invest in companies that cater to the needs of older adults. The aging population represents a long-term growth driver for the healthcare sector and the fund.
- Emerging Markets Healthcare Expansion: Healthcare spending in emerging markets is growing at a rapid pace, driven by rising incomes and increasing access to healthcare services. JHMH can potentially benefit from this trend by investing in healthcare companies that have a presence in emerging markets or that are focused on developing innovative solutions for these markets. The expansion of healthcare in emerging markets presents a significant growth opportunity for the fund.
- Regulatory Tailwinds: Favorable regulatory changes, such as streamlined drug approval processes and increased government funding for healthcare research, can create a positive environment for healthcare companies. JHMH can capitalize on these regulatory tailwinds by investing in companies that are poised to benefit from these changes. Monitoring regulatory developments and adjusting the fund's portfolio accordingly can enhance its performance.
What Are JHMH's Competitive Advantages?
- Established Brand: John Hancock Investment Management has a recognized brand name and a long history in the asset management industry.
- Multifactor Approach: The fund's multifactor investment model aims to enhance returns and manage risk, potentially providing a competitive advantage.
- Targeted Sector Exposure: JHMH offers investors a focused way to invest in the healthcare sector, which can be attractive to those with specific market views.
What Does JHMH Do?
John Hancock Multifactor Health Care ETF (JHMH) is designed to track the performance of the healthcare sector within the U.S. equity market. The fund operates under the umbrella of John Hancock Investment Management, a well-established asset management firm. JHMH invests primarily in securities that constitute its underlying index, which is composed of healthcare companies whose market capitalizations are larger than that of the 1001st largest U.S. company at the time of index reconstitution. This approach ensures that the fund focuses on relatively large and established companies within the healthcare industry. The fund is non-diversified, meaning it invests a significant portion of its assets in a smaller number of holdings compared to a diversified fund. This concentration can lead to potentially higher returns but also exposes investors to greater risk. JHMH's investment strategy employs a multifactor model, which considers various factors such as value, momentum, and quality to select securities within the healthcare sector. This multifactor approach aims to enhance returns while managing risk. JHMH provides investors with a way to gain targeted exposure to the healthcare sector, which includes companies involved in pharmaceuticals, biotechnology, healthcare equipment, and healthcare services. The fund's performance is closely tied to the overall health and growth of the healthcare industry, making it suitable for investors who have a positive outlook on this sector. As an ETF, JHMH offers intraday liquidity and transparency, allowing investors to easily buy and sell shares on the stock exchange.
What Products and Services Does JHMH Offer?
- Invests primarily in securities that compose the fund's index.
- Tracks the performance of the healthcare sector within the U.S. equity market.
- Focuses on healthcare companies with market capitalizations larger than that of the 1001st largest U.S. company.
- Employs a multifactor investment model considering value, momentum, and quality.
- Provides targeted exposure to the healthcare sector, including pharmaceuticals, biotechnology, healthcare equipment, and healthcare services.
- Offers intraday liquidity and transparency as an exchange-traded fund (ETF).
How Does JHMH Make Money?
- Generates revenue through management fees charged as a percentage of the fund's assets under management (AUM).
- Aims to provide investors with returns that closely track the performance of its underlying index, net of fees and expenses.
- Utilizes a multifactor model to select securities within the healthcare sector, seeking to enhance returns while managing risk.
What Industry Does JHMH Operate In?
JHMH operates within the asset management industry, specifically focusing on the healthcare sector. The healthcare industry is driven by factors such as an aging population, technological advancements, and increasing healthcare spending. The competitive landscape includes other healthcare ETFs and mutual funds, such as BLLD, DIVI, DVP, FEVR, and JHMA, each with its own investment strategy and focus. JHMH differentiates itself through its multifactor investment approach and focus on companies with significant market capitalization.
Who Are JHMH's Key Customers?
- Retail investors seeking targeted exposure to the U.S. healthcare sector.
- Institutional investors looking to diversify their portfolios with a sector-specific investment.
- Financial advisors seeking to provide clients with access to the healthcare market through an ETF.
John Hancock Multifactor Health Care ETF (JHMH) Valuation Context
Valued at $20.4M, JHMH is classified as a micro-cap stock.
Key Financial Metrics
Return on equity for John Hancock Multifactor Health Care ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. JHMH trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
JHMH Financials
Bull Case vs Bear Case
Bull Case
- JHMH's focus on healthcare, a traditionally defensive sector, makes it attractive during economic uncertainty. Think of it as the 'flight to safety' we saw during the initial COVID-19 panic, but more targeted.
- Recent insider activity suggests confidence in the fund's long-term prospects, similar to how strong insider buying often preceded rallies in companies like Amazon early on.
- The community sentiment seems to be that healthcare is undervalued right now, potentially setting the stage for a rebound, mirroring the sentiment around tech stocks after the dot-com bubble burst.
- Market perception suggests a growing demand for specialized ETFs, and JHMH's multifactor approach could be seen as a sophisticated way to navigate the healthcare sector, akin to investors seeking actively managed funds during volatile periods.
Bear Case
- The healthcare sector is facing increasing regulatory scrutiny, which could negatively impact JHMH's holdings. It's like the pharmaceutical industry constantly battling drug pricing concerns.
- Community sentiment reveals concerns about the fund's diversification within the healthcare sector, drawing parallels to how over-concentration in certain sectors led to problems in the 2008 financial crisis.
- Market perception indicates potential headwinds from rising interest rates, which could make the fund less attractive compared to fixed-income investments, similar to how bond yields impacted growth stock valuations in 2022.
- Recent market developments suggest a shift away from defensive sectors as investors anticipate an economic recovery, potentially reducing demand for JHMH, much like the shift away from gold when risk appetite increases.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
JHMH Latest News
No recent news available for JHMH.
What Investors Ask About John Hancock Multifactor Health Care ETF (JHMH) — Financial Services
What happened to John Hancock Multifactor Health Care ETF (JHMH) stock?
John Hancock Multifactor Health Care ETF (JHMH) no longer trades on public markets. It was delisted in October 2022. The figures below are historical and are not a current quote.
Can I still buy JHMH shares?
No. JHMH stopped trading on public markets in October 2022, so the shares are not available through a broker. Anything you see quoted for JHMH elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before JHMH stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to John Hancock Multifactor Health Care ETF. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does John Hancock Multifactor Health Care ETF do?
John Hancock Multifactor Health Care ETF (JHMH) is an exchange-traded fund designed to track the performance of the healthcare sector within the U.S. equity market. The fund invests primarily in securities that constitute its underlying index, which is composed of healthcare companies whose market capitalizations are larger than that of the 1001st largest U.S. company.
What are the main risks for JHMH?
The main risks for JHMH include its non-diversified nature, which concentrates risk in a smaller number of healthcare companies. This makes the fund more vulnerable to significant losses if a few key holdings perform poorly.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, limiting the depth of insights.
- The fund's performance is highly dependent on the healthcare sector's overall health and growth.